FR104E - - Google Patents
Info
- Publication number
- FR104E FR104E FR104DA FR104E FR 104 E FR104 E FR 104E FR 104D A FR104D A FR 104DA FR 104 E FR104 E FR 104E
- Authority
- FR
- France
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FR104E true FR104E (OSRAM) |
Family
ID=1341612
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR104D Active FR104E (OSRAM) |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR104E (OSRAM) |
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020203160A1 (ja) | 2019-03-29 | 2020-10-08 | 日東電工株式会社 | 積層体の製造方法、塗装物の製造方法、接合構造体の製造方法、熱転写シート、及び積層体 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| WO2021255447A1 (en) | 2020-06-16 | 2021-12-23 | Ucl Business Ltd | Follicular helper t cell profile for identifying patients with type 1 diabetes suitable fro treatment with ctla-4-ig |
| WO2022094391A2 (en) | 2020-11-02 | 2022-05-05 | Neuvogen, Inc. | Breast cancer tumor cell vaccines |
| WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| WO2023077129A1 (en) | 2021-10-29 | 2023-05-04 | Tambo, Inc. | Tetrazine conjugates for in vivo targeted delivery of a payload |
| WO2023077126A1 (en) | 2021-10-29 | 2023-05-04 | Tambo, Inc. | Trans-cyclooctene conjugates |
| FR3135805A1 (fr) | 2022-05-23 | 2023-11-24 | Idemia France | Procédé de gestion de profils de service d’un élément sécurisé |
-
0
- FR FR104D patent/FR104E/fr active Active
Cited By (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019241730A2 (en) | 2018-06-15 | 2019-12-19 | Flagship Pioneering Innovations V, Inc. | Increasing immune activity through modulation of postcellular signaling factors |
| WO2020203160A1 (ja) | 2019-03-29 | 2020-10-08 | 日東電工株式会社 | 積層体の製造方法、塗装物の製造方法、接合構造体の製造方法、熱転写シート、及び積層体 |
| WO2020227159A2 (en) | 2019-05-03 | 2020-11-12 | Flagship Pioneering Innovations V, Inc. | Methods of modulating immune activity |
| WO2021127217A1 (en) | 2019-12-17 | 2021-06-24 | Flagship Pioneering Innovations V, Inc. | Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly |
| WO2021255447A1 (en) | 2020-06-16 | 2021-12-23 | Ucl Business Ltd | Follicular helper t cell profile for identifying patients with type 1 diabetes suitable fro treatment with ctla-4-ig |
| WO2022094391A2 (en) | 2020-11-02 | 2022-05-05 | Neuvogen, Inc. | Breast cancer tumor cell vaccines |
| WO2023014863A1 (en) | 2021-08-05 | 2023-02-09 | Go Therapeutics, Inc. | Anti-glyco-muc4 antibodies and their uses |
| WO2023034571A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-lamp1 antibodies and their uses |
| WO2023034569A1 (en) | 2021-09-03 | 2023-03-09 | Go Therapeutics, Inc. | Anti-glyco-cmet antibodies and their uses |
| WO2023077129A1 (en) | 2021-10-29 | 2023-05-04 | Tambo, Inc. | Tetrazine conjugates for in vivo targeted delivery of a payload |
| WO2023077126A1 (en) | 2021-10-29 | 2023-05-04 | Tambo, Inc. | Trans-cyclooctene conjugates |
| FR3135805A1 (fr) | 2022-05-23 | 2023-11-24 | Idemia France | Procédé de gestion de profils de service d’un élément sécurisé |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2388454T3 (es) | Derivados de quinolina para el tratamiento de enfermedades inflamatorias | |
| WO2021009146A1 (en) | Antibodies binding to nkg2d | |
| CA2646048A1 (en) | Compositions and methods of use for antibodies of c-met | |
| SK13302003A3 (sk) | Terapeutické prostriedky na zápalové ochorenia čreva | |
| WO2005044294A3 (en) | Method of therapy for cancers expressing the cd40 antigen | |
| EP2301575A1 (en) | Methods of therapy for solid tumors expressing the CD40 cell-surface antigen | |
| JP2023509359A (ja) | 鉄依存性細胞分解の誘導物質との併用抗癌療法 | |
| JP2023509359A5 (OSRAM) | ||
| EP3806848A2 (en) | Increasing immune activity through modulation of postcellular signaling factors | |
| US20250066498A1 (en) | Anti-glyco-lamp1 antibodies and their uses | |
| EP4422693A1 (en) | Trans-cyclooctene conjugates | |
| EP4422696A1 (en) | Tetrazine conjugates for in vivo targeted delivery of a payload | |
| JP2024542021A5 (OSRAM) | ||
| EP3950375A1 (en) | Laminated body manufacturing method, painting object manufacturing method, joining structure manufacturing method, thermal transfer sheet, and laminated body | |
| US20220152169A1 (en) | Colorectal cancer tumor cell vaccines | |
| JP2024536722A (ja) | 抗グリコｃｍｅｔ抗体およびその使用 | |
| JP2024536722A5 (OSRAM) | ||
| US20250101126A1 (en) | Anti-glyco-muc4 antibodies and their uses | |
| JP2024531915A5 (OSRAM) | ||
| US20230258626A1 (en) | Follicular helper t cell profile for identifying patients with type 1 diabetes suitable for treatment with ctla-4-ig | |
| JP2025519087A (ja) | セキュアエレメントのサービスプロファイルを管理する方法 | |
| JP2025519087A5 (OSRAM) |